Talk:Amifampridine
 | This article is rated C-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Amifampridine.
|
External links modified
Hello fellow Wikipedians,
I have just added archive links to one external link on 3,4-Diaminopyridine. Please take a moment to review my edit. If necessary, add {{cbignore}} after the link to keep me from modifying it. Alternatively, you can add {{nobots|deny=InternetArchiveBot}} to keep me off the page altogether. I made the following changes:
- Added archive https://web.archive.org/20150521162420/http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=464814 to http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=464814
When you have finished reviewing my changes, please set the checked parameter below to true to let others know.
An editor has reviewed this edit and fixed any errors that were found.
- If you have discovered URLs which were erroneously considered dead by the bot, you can report them with this tool.
- If you found an error with any archives or the URLs themselves, you can fix them with this tool.
Cheers.—cyberbot IITalk to my owner:Online 14:41, 18 January 2016 (UTC)
Unsupported/Incorrect Information
These two sentences were moved to Talk as they are not supported by the references cited and appear to be incorrect. The first statement mistakes the a type of FDA citation ("483") with the number of citations. The second statement refers to a document which appears to endorse use of the free base for LEMS treatment despite the deficit of preclinical toxicology and pharmacology studies.
- Other commentators noted, however, that Jacobus was not able to meet the needs of all people who could benefit from the drug via its free program, and that its manufacturing practices had quality control problems, with 483 FDA citations in 2011 and 2012.[1] Similarly, at the urging of Assistance Publique-Hôpitaux de Paris, the French drug authority had reviewed the use of the free base in light of the manufactured phosphate form in 2006, and had urged doctors in France not to use the free base form due to quality issues.[2]
- ^ Cite error: The named reference
Stat2016was invoked but never defined (see the help page). - ^ "Point d'information sur l'utilisation de la 3.4 diaminopyridine". ANSM : Agence nationale de sécurité du médicament et des produits de santé. December 18, 2006.